Clinical trials: Zoledronic acid, open to volunteers
Neuroblastoma, Rhabdomyosarcoma
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Hematopoietic stem cell transplantation can cure patients with blood cancer and other underlying diseases. αβ-T cell and B cell depletion has been introduced to decrease GVHD and PTLD and has demonstrated effectiveness for…
- Conditions
- Neuroblastoma, Rhabdomyosarcoma, Synovial Sarcoma, Peripheral Nerve Sheath Tumors
- Trial name
- NCT06625190
- Testing
- Miltenyi CliniMACS Prodigy ® system, Zoledronic acid
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Florida
Paget Disease
Zoledronate In the Prevention of Paget's Disease: Long Term Extension
Paget's disease of the bone (PDB) is a metabolic bone disorder which in some individuals can cause pain, bone deformity, arthritis and deafness, although in many patients it does not cause symptoms.
- Trial name
- ZiPP-LTE (NCT03859895)
- Where
- 21 sites in Australia, Belgium and 5 more
- Volunteers
- 287 people
- Sponsor
- University of Edinburgh
Breast Cancer, Stage IV Breast Cancer
Surgery vs. No Surgery for Primary Tumor in De Novo Stage IV Breast Cancer With Solitary Bone Metastases
This is a national multicenter, prospective, randomized controlled trial. The study aims to compare the 5-year overall survival (OS) between patients receiving primary tumor surgery followed by systemic therapy (surgery group)…
- Conditions
- Breast Cancer, Stage IV Breast Cancer, Bone Metastases
- Trial name
- POSITIVE-Bone (NCT07687225)
- Testing
- Primary Tumor Resection, Standard systemic therapy
- Volunteers
- 216 people
- Sponsor
- West China Hospital
Sarcopenia in Elderly
RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients
The objective of this study is to conduct a pragmatic, randomized, double-blind, active-controlled trial to assess the efficacy of receptor activator of nuclear factor-kB ligand (RANKL) inhibition in the treatment of sarcopenia…
- Trial name
- NCT07056478
- Testing
- Denosumab (Prolia), Zoledronic acide (Aclasta)
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Prince of Wales Hospital, Shatin, Hong Kong
With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer
ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers
This is an open-label, single-arm, investigator-initiated study conceived as a dose expansion cohort of the study D3-002, which evaluated ETC-159 in combination with pembrolizumab in solid tumors.
- Trial name
- ETC-159-02 (NCT06513624)
- Testing
- ETC-159, Pembrolizumab, Denosumab / Zoledronic Acid
- Where
- 2 sites in Singapore
- Volunteers
- 16 people
- Sponsor
- National University Hospital, Singapore
Carcinoma, Non-Small-Cell Lung
Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.
The purpose of this study is to assess percentage reduction in the of urine NTX and serum CTX , in patients with NSCLC and bone metastases 1) with actionable driver oncogene on standard of care (SOC) TKI at 3 months post…
- Trial name
- NCT03958565
- Testing
- Tyrosine Kinase Inhibitor, Zoledronic Acid 4 MG/100 ML Intravenous Solution [ZOMETA], Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- University of Colorado, Denver
Osteomyelitis Chronic
EFFICACY AND SAFETY OF ZOLEDRONATE VERSUS PLACEBO ON PAIN AT WEEK 12 IN PEDIATRIC PATIENTS WITH CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS
Chronic recurrent multifocal osteomyelitis (CRMO) is a rare auto-inflammatory bone disease that primarily affects children and/or adolescents at a median age of 10 years.
- Trial name
- POMREP (NCT07668583)
- Testing
- Zoledronic Acid / Zoledronate 4 MG/100 ML Intravenous Solution, NaCL 0.9% Intravenous Solution
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Giant Cell Tumor of Bone
Zoledronic Acid-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Bone Tumor After Intralesional Curettage
The purpose of this study is to investigate whether zoledronic acid-loaded bone cement (4mg ZOL+ gentamicin PMMA ) as adjuvant method can decrease local recurrence in patients with giant cell bone tumor following intralesional…
- Trial name
- NCT05595603
- Testing
- 4mg ZOL loaded gentamicin PMMA, gentamicin PMMA
- Where
- China
- Volunteers
- 153 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Congenital Dyserythropoietic Anemia (CDA)
Zoledronic Acid Treatment in Patients With Congenital Dyserythropoietic Anemia
Background: Congenital Dyserythropoietic Anemia (CDA) is a group of rare hereditary blood disorders characterized by ineffective erythropoiesis, leading to chronic anemia and organ damage.
- Trial name
- NCT07471516
- Testing
- zoledronic acid
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Chronic Kidney Disease, Osteoporosis
Pharmacokinetics of Zoledronic Acid in Patients on Dialysis
Osteoporosis is a frequent complication of chronic kidney disease (CKD) on dialysis, with an estimated prevalence of approximately 40%. It is associated with increased fracture risk, reduced quality of life, and higher mortality.
- Conditions
- Chronic Kidney Disease, Osteoporosis, Dialysis
- Trial name
- ZADIAL (NCT07741136)
- Testing
- Zoledronic Acid Injection, 5.0 mg, single dose, Zoledronic Acid Injection, 2.5 mg, single dose
- Where
- Brazil
- Volunteers
- 24 people
- Sponsor
- University of Campinas, Brazil
Osteoporosis
Preserving Geriatric Muscle With an Osteoporosis Medication
Our goal is to demonstrate efficacy of the novel agent Denosumab to improve or preserve muscle health, strength, mobility and function in frail older adults.
- Trial name
- NCT06118905
- Testing
- Denosumab 60 MG/ML, Zoledronic Acid 5Mg/Bag 100Ml Infusion
- Where
- United States
- Volunteers
- 155 people
- Sponsor
- Chrissy Kistler
MDR-TB, Immunotherapy
A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB
A Exploratory Study of drug combination (zoledronic acid/interleukin 2) that specifically amplifies Vγ2Vδ2 T cells in combination with anti-tuberculosis chemotherapy for the treatment of MDR-TB.
- Trial name
- NCT05493267
- Testing
- Vγ2Vδ2 T lymphocyte-based immunotherapy, Treatment regimens for MDR-TB
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
HIV Infected Individuals, Osteopenia
Zoledronic Acid for the Prevention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naive HIV Positive Individuals
The goal of this clinical trial is to learn if zolendric acid can prevent the anticipated deterioration of bone mass after antiviral treatment initiation for people that were recently diagnosed with HIV.
- Trial name
- NCT06762730
- Testing
- Zoledronic Acid 5 mg/Bag 100 ml Inj
- Where
- 3 sites in Israel
- Volunteers
- 110 people
- Sponsor
- Hadassah Medical Organization
Critical Illness, Osteoporosis
Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults
The Bone Zone trial is a prospective, multi-centre, double-blind, phase II, randomised controlled trial evaluating the effect of denosumab or zoledronic acid compared to placebo on change in bone mineral density over one year in…
- Trial name
- BoneZone (NCT04608630)
- Testing
- Denosumab 60 MG/ML, Zoledronic Acid 5Mg/Bag 100Ml Inj, Sodium Chloride 0.9% or 5% Dextrose Intravenous
- Where
- 22 sites in Australia, New Zealand
- Volunteers
- 450 people
- Sponsor
- Australian and New Zealand Intensive Care Research Centre
Histologically Confirmed Breast Cancer ,Diagnosis of Bone Metastasis
Effect of Zoledronic Acid Treatment on Bone-related Events in Breast Cancer Patients With Bone Metastases: a Prospective, Multicenter, Real-world Study
non-intervention、real world study； Effect of timing and regular treatment of zoledronic acid on the incidence of SREs in breast cancer patients
- Trial name
- NCT05480189
- Testing
- Non-intervention
- Volunteers
- 1,000 people
- Sponsor
- Zhejiang Cancer Hospital
Neuroblastoma, Refractory Neuroblastoma
Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma
The goal of this clinical trial is to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) of allogeneic expanded γδ T cells when delivered with Dinutuximab, temozolomide, irinotecan, and zoledronate in…
- Conditions
- Neuroblastoma, Refractory Neuroblastoma, Relapsed Neuroblastoma, Relapsed Osteosarcoma
- Trial name
- Aflac-NBL-2002 (NCT05400603)
- Testing
- Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Emory University
Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
This is a phase Ib/II study evaluating the safety and efficacy of zunsemetinib (ATI-450) with capecitabine in patients with hormone receptor-positive and HER2-negative (HR+/HER2-) metastatic breast cancer (MBC).
- Trial name
- NCT06374459
- Testing
- Zumsemetinib, Capecitabine, Zoledronic acid
- Where
- 3 sites in United States
- Volunteers
- 152 people
- Sponsor
- Washington University School of Medicine
Hip Fractures, Osteoporosis
A Study to Improve the Collaboration Between Primary and Secondary Health Care on the Treatment of Osteoporosis After a Hip Fracture.
This is a study to improve the collaboration between primary and secondary health care on the treatment of osteoporosis after a hip fracture.
- Conditions
- Hip Fractures, Osteoporosis, Zoledronic Acid, Ambulant Nurse
- Trial name
- NCT05904353
- Testing
- Ambulant nurse-assisted administration of zoledronic acid, Usual care
- Where
- Norway
- Volunteers
- 200 people
- Sponsor
- University Hospital, Akershus
Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma
Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases
This is a single-institution, phase 2 trial of zanzalintinib plus investigator-choice bone-strengthening agent in patients with metastatic renal cell carcinoma (RCC) with bone metastases whose disease has advanced on 1-3 prior…
- Conditions
- Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic, Clear Cell Renal Cancer
- Trial name
- ZAMBONI (NCT07043608)
- Testing
- Zanzalintinib, Investigator Choice of Bone Strengthening Agents (BSA), Non-Investigational Radiation Therapy (RT)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Kelly Fitzgerald, MD
Postmenopausal Osteoporosis
StrAtegies For Zoledronic Acid Post-dEnosumab Discontinuation in Postmenopausal oSTeoporosis
Denosumab (Dmab) is a treatment for postmenopausal osteoporosis. However, its withdrawal is associated with a rebound phenomenon associated with an unexpected increased risk of vertebral fractures.
- Trial name
- SAFEST (NCT06767150)
- Testing
- a second infusion of ZOL when crosslaps levels reach 300 pg/mL, a rescue second infusion at month-12 (standard traitment)
- Where
- 17 sites in France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Toulouse